Duke Kunshan University
Suzhou, Jiangsu, 215316, China
NCT Number: NCT06975501
This study is a cluster randomized controlled trial with a 2×2 factorial design conducted in community health centers in Kunshan, Harbin, Wuhan, Beijing and Shanghai. It aims to evaluate the independent and combined effects of exercise and cognitive interventions on intrinsic capacity and related health outcomes among stroke survivors aged 60 years and older with hypertension or type 2 diabetes mellitus. Participants will receive either exercise training, cognitive training, combined training, or usual care over 12 months, followed by a 12-month follow-up. Findings will inform integrated health management strategies for older adults with multimorbidity.
This study is active but is not currently recruiting participants.
Notify Me60 year and older
All sexes
Interventional
Not applicable
Suzhou, Jiangsu, 215316, China
This study is a community-based cluster randomized controlled trial with a 2×2 factorial design, conducted in community health centers in Kunshan (Jiangsu), Wuhan (Hubei), Harbin (Heilongjiang), Beijing and Shanghai, China. A total of 480 stroke survivors aged 60 years and above with comorbid hypertension or type 2 diabetes mellitus will be recruited. Participants will be randomly assigned to one of four groups: exercise intervention only, cognitive intervention only, combined intervention, or control (usual care). The interventions, including aerobic-balance physical training and structured cognitive training, will be delivered twice weekly for 12 months, followed by a 12-month observational follow-up.
The primary outcome is intrinsic capacity (IC), assessed using the World Health Organization Integrated Care for Older People (WHO ICOPE) framework. Secondary outcomes include systolic blood pressure, quality of life (EuroQol 5-Dimension 5-Level, EQ-5D-5L), medication adherence, physical activity (Metabolic Equivalent of Task minutes per week, MET-min/week), and healthcare utilization. Data will be collected at baseline, 6, 12, and 24 months.
Intervention effects and trajectories over time will be analyzed using two-way analysis of variance (ANOVA), repeated measures ANOVA, and mixed-effects models. Implementation outcomes will be evaluated following the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. The study aims to generate evidence for integrated health management strategies for older adults with stroke and multimorbidity in urban China.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive twice-weekly aerobic and balance training sessions, with medication compliance education.
Participants will participate in twice-weekly structured cognitive training sessions, with medication compliance education.
Time frame: 24 months
Assessment of intrinsic capacity using the World Health Organization Integrated Care for Older People (WHO ICOPE) framework.
Time frame: 24 months
The Short Physical Performance Battery (SPPB) is a validated, performance-based tool designed to assess lower extremity function in older adults. It consists of three components: a balance test, a gait speed test, and a chair stand test. Each component is scored on a scale from 0 to 4, with a total score ranging from 0 (worst performance) to 12 (best performance).
Time frame: 24 months
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a widely validated screening tool for mild cognitive impairment. The MoCA evaluates multiple cognitive domains, including attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.
The MoCA score ranges from 0 to 30, with higher scores indicating better cognitive function. A score of 26 or above is generally considered within the normal range.
Assessments will be conducted at baseline and at regular intervals across the 24-month study period to track changes over time.
Time frame: 24 months
Psychological well-being will be assessed using the Cornell Scale for Depression in Dementia (CSDD), a clinician-administered instrument specifically designed to assess signs of depression in individuals with cognitive impairment, including those with dementia. The CSDD incorporates information from both patient interviews and caregiver reports to increase the reliability of the assessment.
The scale includes 19 items, each scored from 0 (absent) to 2 (severe), resulting in a total score ranging from 0 to 38. Higher scores indicate more severe depressive symptoms, reflecting poorer psychological well-being. A score of ≥12 suggests probable major depression, while scores between 8-11 indicate possible depression.
CSDD assessments will be performed at baseline and repeated at regular intervals throughout the 24-month study period.
Time frame: 24 months
Vitality will be assessed using the Mini Nutritional Assessment (MNA), a validated screening and assessment tool designed to identify older adults at risk of malnutrition or undernutrition, which are closely associated with reduced physical vitality and frailty.
The full MNA consists of 18 items, producing a total score ranging from 0 to 30. Higher scores indicate better nutritional status, reflecting greater vitality and overall health.
A score of 24-30 indicates normal nutritional status. Scores 17-23.5 suggest risk of malnutrition. Scores <17 indicate malnutrition. The MNA will be administered at baseline and at regular follow-ups over the 24-month study period to monitor changes in patients' nutritional status and associated vitality.
Time frame: 24 months
measured using the 4-item Morisky Green Levine Scale-4 (MMAS-4). The 4-item Morisky Green Levine Medication Adherence Scale (MMAS-4), is a validated self-reported questionnaire that evaluates patients' behaviors related to medication-taking. The scale consists of 4 yes/no questions, with each "yes" answer scored as 1 and each "no" as 0. The total score ranges from 0 to 4, with higher scores indicating lower adherence.
A score of 0 indicates high adherence. 1-2 indicates medium adherence. 3-4 indicates low adherence.
Time frame: 24 months
Measurement of physical activity levels in metabolic equivalent of task (MET) minutes per week.
Time frame: 24 months
Change in the systolic blood pressure.
Time frame: 24 months
change in weight
Time frame: 24 months
change in height
Time frame: 24 months
participants' neck circumference
Time frame: 24 months
Participants' waist circumference
Time frame: 24 months
measured by timed-up-and-go test, a simple and quick functional mobility test that requires the participants to stand up, walk 3 meters, turn, walk back, and sit down
Time frame: 24 months
The Geriatric Depression Scale - 15 item version (GDS-15) is a self-report questionnaire designed to screen for depression in older adults. It contains 15 yes/no questions that assess mood, motivation, energy levels, and outlook on life over the past week. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms, thus reflecting a worse outcome. Each depressive answer is scored as 1 point, and the total score is the sum of these points. Commonly used cut-off points are: 0-4 (no depression), 5-8 (mild depression), 9-11 (moderate depression), and 12-15 (severe depression).
Time frame: 24 months
measured using EuroQol-5 Dimensions-5L (EQ5D-5L). EQ-5D-5L descriptive system comprises the following five dimensions, each describing a different aspect of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. For each domain, the total scores range from 0 (indicating no problem) to 5 (indicating unable to/extreme problems). In addition, the participants were required to assess how their health is today by write a number from 0 to 100 on the numbered scale. 100 means the best health the participant can image, 0 means the worst health the participant can image.
Time frame: 24 months
The factors include lack of exercise, alcohol, diet, obesity, and smoking, and will be collected through questionnaire.
Time frame: 24 months
measured by the basic activities of daily living (ADL). The basic ADL include the following categories: Ambulating, Feeding, Dressing, Personal hygiene, Continence, and Toileting. The ADL score ranges from 0 to 12. Limitation in ADL was defined as being scored greater than 0 on ADL scales, i.e., having some or severe limitation in at least one ADL item. Higher scores mean a worse functional independence.
Time frame: 24 months
measured by the Lawton Instrumental Activities of Daily Living (IADL) Scale to evaluate independent living skills. The scale measures eight domains of function, including food preparation, housekeeping, laundering. The IADL score ranges from 0 to 14. Limitation in IADL was defined as being scored greater than 0 on IADL scales, i.e., having some or severe limitation in at least one IADL item. Higher scores mean a worse functional independence.
Time frame: 24 months
measured using modified Rankin Scale (ranged 0 (no symptom) to 5 severe disability)
Time frame: 24 months
Assessed by determining whether participants had additional diseases diagnosed in the hospital, excluding stroke
Time frame: 24 months
Grip strength (kilogram) will be estimated through the dynamometer (YuejianTM WL-1000, Nantong, China). Trained examiners will instruct people to hold the dynamometer and squeeze the handle for a few seconds. This study both measures right and left-hand grip strength twice in each hand. The grip strength will be recorded separately. If the average grip strength of both right and left hand of is all less than the criteria (man < 30 kg, woman < 20 kg), it is defined as weak grip strength.
Time frame: 24 months
Measured by the total number of months during the 24-month follow-up period that the patient continuously takes the prescribed medication.
Time frame: 24 months
The number of hospital visits (both inpatient and outpatient) will be measured during the 24-month follow-up period. This will include the total number of hospital admissions, along with any follow-up outpatient visits associated with hospital care. Unit of Measure: Number of hospital visits
Time frame: 24 months
The number of emergency room visits will be assessed over the 24-month period. This includes any visits to the emergency room for acute health concerns or urgent care needs.
Unit of Measure: Number of emergency room visits
Time frame: 24 months
The number of outpatient visits (excluding emergency room and inpatient visits) will be measured throughout the 24-month study period. This includes visits to primary care providers, specialists, and other outpatient services.
Unit of Measure: Number of outpatient visits
Time frame: 24 months
Presence of chronic diseases reported by participants through a structured questionnaire. Unit of Measure: Count of documented diseases
Time frame: 24 months
Number and type of diagnosed chronic diseases retrieved from participants' medical insurance claims data. Unit of Measure: Count of documented diseases
Duke Kunshan University
Other
A Community-Based 2×2 Factorial Randomized Controlled Trial Evaluating a Multicomponent Physical and Cognitive Intervention for Older Adults With Stroke and Comorbid Chronic Conditions in Urban China
Acronym: CEEEC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06094491
Body Weight, Brain Diseases
Chicago, Illinois, United States
View Trial DetailsNCT00005487
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT06347484
Body Weight, Brain Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT07151430
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details